RETRACTION







Retraction to: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection

Andrew Hill, Anna Garratt, Jacob Levi, Jonathan Falconer, Leah Ellis, Kaitlyn McCann, Victoria Pilkington, Ambar Qavi, Junzheng Wang, and Hannah Wentzel

¹Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK, ²Department of Infectious Diseases, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, UK, ³Department of Infectious Diseases, Chelsea and Westminster Hospital, Imperial NHS Trust, London, UK, ⁴Department of Infectious Diseases, Chelsea and Westminster Hospital, Imperial NHS Trust, London, UK, ⁵Faculty of Medicine, Imperial College London, London, UK, and ⁶Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK

Open Forum Infectious Diseases, Volume 8, Issue 11, November 2021, ofab358, https://doi.org/10.1093/ofid/ofab358

On July 6, 2021, *Open Forum Infectious Diseases* published the article "Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection" by Hill, et al. Subsequently, we and the authors learned that one of the largest studies on which this analysis was based was withdrawn due to fraudulent data; additional problems have emerged regarding other studies included in the original paper.

An editorial Expression of Concern was first published under this record as the authors revised their analysis for resubmission.

The authors submitted and published a corrected version of the analysis with commentary on assessing trial quality while creating meta-analyses, available to read in OFID: "Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud" by Hill et al., https://doi.org/10.1093/ofid/ofab645. The original analysis has been retracted.

Correspondence: Andrew Hill, PhD, Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, UK (microhaart@aol.com).

Open Forum Infectious Diseases®2022

© Infectious Diseases Society of America 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://doi.org/10.1093/ofid/ofac056